CNBC Make It
March 29, 2021
This biotech start-up is working overtime to develop a second-wave, mutation-resistant Covid-19 vaccine.
Rajaniemi’s then-six-person start-up wasn’t going to be able to compete with the likes of Pfizer and AstraZeneca, but HelixNano, as it’s known, had a different goal: Create a better, second-generation vaccine against the novel coronavirus.
Read More